Evidence item

Independent ASCO-focused reporting confirms 40 HERBOT participants and a 55% objective response rate for the four-drug regimen. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15741

Source: HERBOT at ASCO 2026: Trastuzumab, Nivolumab, Gemcitabine, and Cisplatin in HER2-Positive Biliary Tract Cancer · locator {} · excerpt hash sha256:241235c62c1ec36431de56a66f4761d94e30df207f57be8a5877a14419e2c5bb

A total of 40 patients were included. ... The primary endpoint was met, with an objective response rate of 55% (95% CI: 38.5–70.7). Responses included 1 complete response and 21 partial responses.